Yuhan Corporation announced on Monday that it will enter the U.S. digital healthcare market through a strategic partnership between its American subsidiary, Yuhan USA, and digital healthcare innovator Huinno.
The agreement focuses on introducing Huinno’s artificial intelligence (AI) powered electrocardiogram (ECG) monitoring solutions (MemoPatch M, MemoQ, MemoCare) and clinical prediction tool Vital Picasso to the U.S. market, aiming to expand their market share.
The collaboration will encompass building U.S. sales channels, developing local marketing and branding strategies, navigating regulatory hurdles, providing logistical support, and exploring new business opportunities.
MemoPatch M is an ultra-lightweight wearable ECG monitor that can record continuously for up to eight days. It’s designed to function reliably even during defibrillation, meeting the strictest international medical device safety standard, Type CF Defib-proof. The device received the U.S. Food and Drug Administration (FDA) 510(k) clearance last year.
MemoQ, which includes MemoPatch M, is a smart AI telemetry solution that analyzes hospitalized patients’ ECG data in real-time. It alerts medical staff to early signs of abnormalities, supporting rapid clinical decision-making.
The system can be integrated into existing hospital infrastructure without additional network installations, significantly improving patient management efficiency in both intensive care units (ICUs) and general wards.
MemoCare is a long-term ECG analysis solution using AI to interpret data collected over up to 14 days. It extends precise diagnostics beyond short-term in-hospital monitoring to home and outpatient settings.
Vital Picasso, developed by Huinno’s subsidiary Huinno AIM, is a predictive analytics tool that processes vital sign data from general ward patients. It can forecast major clinical deteriorations such as hypotension, hypoxia, and cardiac arrest. The Korean Ministry of Food and Drug Safety recently designated it as an innovative medical device.
A Yuhan Corporation spokesperson expressed optimism about their U.S. market entry, stating that it believes the ECG monitoring and clinical prediction solutions, including MemoPatch M and MemoQ, will significantly enhance patient care efficiency in ICUs and general wards by enabling faster, more informed clinical decisions.